SciVision Biotech Announces Board Approval of Q1 2026 Consolidated Financial Report
📋 Article Processing Timeline
- 📰 Published: May 14, 2026 at 09:00
- 🔍 Collected: May 15, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 15, 2026 at 08:11 (11 min after Collected)
SciVision Biotech Inc. announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026 on May 14, 2026. For the reporting period from January 1 to March 31, 2026, the company recorded cumulative operating revenue of NT$205,322 thousand and an operating gross profit of NT$145,204 thousand. Net income attributable to owners of the parent was NT$21,956 thousand, resulting in a basic earnings per share of NT$0.29. Total assets at the end of the period were NT$2,751,444 thousand.